The Law Offices of Frank R. Cruz announces an investigation of Emergent BioSolutions Inc. (“Emergent BioSolutions” or the “Company”) (NYSE: EBS) on behalf of investors concerning the Company’s possible violations of federal securities laws.

On August 5, 2026, Emergent reported results for the quarter ended June 30, 2026. Among other items, Emergent announced, among other things, a $191.3 million non-cash impairment charge on the NARCAN asset group, driving a GAAP net loss of $180.2 million. The Company also cut full year revenue guidance approximately 10.8% at the midpoint. Management attributed its results to “increased competitive intensity with implications for our near to medium term outlook and the book value of our NARCAN asset group”

On this news, Emergent’s stock fell $2.23 per share, or 29.58%, to close at $5.31 on August 6, 2026, thereby injuring investors.